Advertisement

Humoral Immune Response to Human Cytomegalovirus

Diagnostic and Clinical Implications
  • Maria Paola Landini
  • Tiziana Lazzarotto
  • Paola Dal Monte

Abstract

Human Cytomegalovirus (CMV) is associated with several diseases in immunocompromised individuals. Diagnosis of CMV infection can be obtained by direct demonstration of the virus or virus components in pathological materials or indirectly through serology. Serological diagnosis gives only indirect evidence of the presence of the virus, and is problematic because of the immunological disorders occurring in most patients at risk of developing a CMV infection. Furthermore, antigenic reagents used in commercially available kits are not standardized and discordant results are often obtained. However serology is cheaper than the other diagnostic tests, requires a short execution time, is safe and can be completely automized.

Furthermore the rapid evolution triggered by the detailed study of the viral genome and its antigenic gene products has allowed a rapid progress in CMV serology. Therefore, it is worthwhile exploring the possible application fields in which the use of serology is justified now adays. This is what this review will attempt to do in general terms and in bone marrow transplant recipients in particular.

Keywords

Primary Infection Human Cytomegalovirus Cytomegalovirus Infection Solid Organ Transplant Recipient Bone Marrow Transplant Recipient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    . Ho M Cytomegalovirus. Biology and Infection. II Edition. Plenum Medical Press, New York and London, 1991.Google Scholar
  2. 2.
    . Britt, W.J. Infections associated with human cytomegalovirus. Chapter 2 of “Herpesvirus Infections” R. Glaser and J.F. Jones Editors, Marcel Dekker, Inc, New York. 1994.Google Scholar
  3. 3.
    . Landini M P. New approaches and perspectives in cytomegalovirus diagnosis. Prog Med Virol 1993; 4, 157 – 177.Google Scholar
  4. 4.
    . Epstein JB, Phillips K, Sherlock CH Viral serology after bone marrow transplantation. Viral immunol 1991; 4: 133 – 137.PubMedCrossRefGoogle Scholar
  5. 5.
    . The TH, van der Berg AP, van Son WJ, et al. Recent advances in the early and reliable immunodiagnosis of cytomegalovirus infection in immunocompromised hosts, in Landini MP, ed: Progress in Cytomegalovirus Research, Elsevier, Amsterdam, 1991: 209.Google Scholar
  6. 6.
    . Alford, CA, Hayes K, Britt W. Primary cytomegalovirus infection in pregnancy: Comparison of antibody responses to virus-encoded proteins between women with and without intrauterine infection. J Inf Dis 158: 917 – 924, 1988.CrossRefGoogle Scholar
  7. 7.
    . Boppana, SB, Pass R, Britt W. Virus-specific antibody responses in mothers and their newborn infants with asymptomatic congenital infections. J Inf Dis 167: 72 – 77, 1993.CrossRefGoogle Scholar
  8. 8.
    . Blackburn NK, Besselaar TG, Schoub BD, O’Connell KF. Differentiation of primary cytomegalovirus infection from reactivation using the urea denaturation test for measuring antibody avidity. J Med Virol 33: 6 – 9, 1991.PubMedCrossRefGoogle Scholar
  9. 9.
    . Gleaves CA, Wendt SF, Dobbs DR, Meyers JD. Evaluation of the CMV-CUBE assay for detection of Cytomegalovirus serological status in marrow transplant patients and marrow donors. J Clin Microbiol 28: 841 – 842, 1990.PubMedGoogle Scholar
  10. 10.
    . Koerner K, Kilian D, Zimmermann B, Nebel Schickel H, Horn J. Comparison of four different ELISAs and indirect immunofluorescence for screening of blood donors for antibodies to Cytomegalovirus. Biotest Bull 4: 119 – 123, 1990.Google Scholar
  11. 11.
    . Kraat YJ, Hendrix RMG, Landini MP, Bruggeman CA. Comparison of four techniques for detection of antibodies to Cytomegalovirus. J Clin Microbiol 30: 522 – 524, 1992.PubMedGoogle Scholar
  12. 12.
    . Gutierrez J, del Carmen Maroto C, Piedrola G. Evaluation of a new reagent for anti-cytomegalovirus and anti-Epstein barr Virus immunoglobulin G. J Clin Microbiol 32: 2603 – 2605, 1994.PubMedGoogle Scholar
  13. 13.
    . Doerr HW and Albert S. New developments in CMV antibody screening. Biotest Bull 4: 125 – 130, 1990.Google Scholar
  14. 14.
    . Landini, M.P. Antibody response to human cytomegalovirus proteins. Rev Med Virol 2: 63 – 72, 1992CrossRefGoogle Scholar
  15. 15.
    . Landini MP, Rossier E, Schmitz H. Antibodies to human cytomegalvirus structural polypeptides during primary infection. J Virol Meth 22: 309–317, 1988,CrossRefGoogle Scholar
  16. 16.
    . Vornhagen R, Plachter B, Hinderer W, The TH, Van Zanten J, Matter L, Schmidt CA, Sonneborn HH, Jahn G. Early serodiagnosis of acute cytomegalovirus infection by Enzyme-linked immunosorbent assay using recombinant antigens. J Clin Microbiol 32: 981 – 986, 1994.PubMedGoogle Scholar
  17. 17.
    . Landini MP, Guan MX, Jahn G, Lindenmeier W, Mach M, Ripalti A, Necker A, Lazzarotto T, Plachter B. Large scale screening of human sera with Cytomegalovirus recombinant antigens. J Clin Microbiol 28: 1375 – 1379, 1990PubMedGoogle Scholar
  18. 18.
    . Scholl BC, Von Hintzestein B, Borisch B, Traupe B, Broker M, Jahn G. Procaryotic expression of immunogenic polypeptides of the large phosphoprotein (ppl50) of human cytomegalovirus. J Gen Virol 69: 1195 – 1204, 1988PubMedCrossRefGoogle Scholar
  19. 19.
    . Novak J, Sova P, Krchnak V, Hamsikova E, Zavadova H E Mapping of serologically relevant regions of human cytomegalovirus phosphoprotein pp150 using synthetic peptides. J Gen Virol 72: 1409 – 1413, 1991PubMedCrossRefGoogle Scholar
  20. 20.
    . Plachter B, Wieczorek L, Scholl B-C, Ziegelmaier R and Jahn G. Detection of Cytomegalovirus antibodies by an enzyme linked immunosorbent assay using recombinant polypeptides of the large phosphorylated tegument protein pp150. J Clin Microbiol 30: 201 – 206, 1992PubMedGoogle Scholar
  21. 21.
    . Meyer H, Bankier AT, Landini MP, Brown CM, Barrell BG, Ruger B, Mach M. Identification and procaryotic expression of the gene coding for the highly immunogenic 28Kilodalton st5ructural phosphoprotein (pp28) of human cytomegalovirus. J Virol 62: 2243 – 2250, 1988.PubMedGoogle Scholar
  22. 22.
    . Vornhagen R, Plachter B, Hinderer W, Bein G, The TH, Matter L, Sonneborn HH, Jahn G. Serodiagnosis of acute and past HCMV-infection using recombinant autologous fusion proteins. Cytomegalovirus workshop, Stockholm 1995Google Scholar
  23. 23.
    . Snydman DR. Cytomegalovirus Immunoglobulins in the prevention and treatment of Cytomegalovirus disease. Rev Inf Dis 12 (sup7): 839–848.Google Scholar
  24. 24.
    . Mach M. and Britt W Immunoprophylaxix of human cytomegalovirus infections in Progress in Progress in Cytomegalovirus Research, MP Landini Ed, 1991, Elsevier, Amsterdam.Google Scholar
  25. 25.
    . Utz U, Britt WJ, Vugler L, Mach M. Identification of a neutralizing epitope on glycoprotein gp58 of human cytomegalovirus. J Virol 63: 1995 – 2001, (1989).PubMedGoogle Scholar
  26. 26.
    . Rasmussen L, Matkin C, Spaete R, Pachi C, merigan TC. Antibody response to human cytomegalovirus glycoprotein B gB and gH after natural infection in humans. J Inf Dis 164: 835 – 842, 1991.CrossRefGoogle Scholar
  27. 27.
    . Marshall GS, Rabalais GP, Stout GG, Waldeyer SL. (1992) Antibodies to recombinant-derived glycoprotein B after natural cytomegalovirus infection correlate with neutralizing activity. J Inf Dis 165: 381–384, 1992.CrossRefGoogle Scholar
  28. 28.
    . Kniess N, Mach M, Fay J Britt WJ. Distribution of linear antigenic sites on glycoprotein gp55 of human cytomegalovirus. J Virol 65: 138 – 146, 1991.PubMedGoogle Scholar
  29. 29.
    . Meyer H, Sundqvist VA, Pereira L, Mach M. Glycoprotein gp116 of human cytomegalovirus contains epitopes strain common and strain-specific antibodies. J Gen Virol 73: 2375 – 2383, 1992.PubMedCrossRefGoogle Scholar
  30. 30.
    . Silvestri M, Sundqvist VA, Ruden U, Wharen B. Characterization of a major antigenic region on gp55 of human cytomegalovirus. J Gen Virol 72: 3017 – 3023, 1991.PubMedCrossRefGoogle Scholar
  31. 31.
    . Wagner B, Kropff B, Kalbacher H, Britt WJ, Sundqvist VA, Ostberg L, Mach M. A continuous sequence of more than 70 aminoacids is essential for antibody binding to the dominant antigenic site of glycoprotein gp58 of human cytomegalovirus. J Virol 66: 5290 – 5297, 1992a.Google Scholar
  32. 32.
    . Ohlin M, Sundqvist, VA, Gilljam G, Ruden U, Gombert FO, Wharen B, Borrebaeck CA. Characterization of human monoclonal antibodies directed against the pp65 matrix antigen of human cytomegalovirus. Clin Expt Immunol 84: 508 – 514, 1991.Google Scholar
  33. 33.
    . Kropff B, Landini MP, Mach M. An Elisa using recombinant proteins for the detection of neutralizing antibodies against human cytomegalovirus. J Med Virol 39: 187 – 195, 1993.PubMedCrossRefGoogle Scholar
  34. 34.
    . Urban M, Britt WJ, Mach M. The dominant linear neutralizing antibody-binding site of glycoprotein gp86 of human cytomegalovirus is strain-specific. J Virol 66: 1303 – 1311, 1992.PubMedGoogle Scholar
  35. 35.
    . Simpson JA, Chow JC, Baker J, Avdalovic N, Yuan S, Au D, Co MS, Vasquez M, Britt WJ, Coelingh KL. Neutralizing monoclonal antibodies that distinguish three antigenic sites on human glycoprotein H have distintict binding sites. J Virol 67: 489 – 496, 1993.PubMedGoogle Scholar
  36. 36.
    . Lazzarotto T, Dalla Casa B, Campisi B, Landini MP. Enzyme-linked immunoadsorbent assay for the detection of cytomegalovirus-IgM: Comparison between eight commercial kits, immunofluorescence and immunoblotting. J Clin Lab Anal 1992; 6: 216 – 218.PubMedCrossRefGoogle Scholar
  37. 37.
    . Landini MP, Ripalti A, Sra K, Pouletty P. Human cytomegalovirus structural proteins: immune raction against pp150 synthetic peptides. J Clin Microbiol 1991; 29: 1868 – 1872.PubMedGoogle Scholar
  38. 38.
    . Ripalti A, Ruan Q, Boccuni MC, Campanini F, Bergamini G and Landini MP Construction of a polyepitope fusion antigens of human cytomegalovirus ppUL32: reactivity with human antibodies J Clin Microbiol 1994; 32: 358 – 363.Google Scholar
  39. 39.
    . Ripalti A, Boccuni MC, Campanini F, Bergamini G, Lazzarotto T, Battista MC, Dalla Casa B, Landini MP. Construction of a polyepitope fusion antigen of human cytomegalovirus ppUL32 and detection of specific antibodies by ELISA. Microbiologica 18: 1 – 12, 1994Google Scholar
  40. 40.
    . Ripalti A, Dal Monte P, Boccuni, MC, Campanini, F, Lazzarotto T, Campisi B, Ruan Q, Landini MP. Prokaryotic expression of a large fragment of the most antigenic cytomegalovirus DNA-binding protein (ppUL44) and its reactivity with human antibodies. J Virol Methods 1994; 46: 39 – 50.PubMedCrossRefGoogle Scholar
  41. 41.
    . Lindenmeier W, Necker A, Krause S, Bonewald R, Collins J. Cloning and characterization of major antigenic determinants of human cytomegalovirus AD169 seen by the human immune system. Arch Virol 1990; 113: 1 – 16.CrossRefGoogle Scholar
  42. 42.
    . Vornhagen, R, Hinderer, W, Sonneborg, HH, Bein, G, Matter, L, The, TH, Jahn, G, Plachter, B. The DNA-binding protein pUL57 of Human Cytomegalovirus is a major terget antigen for the immunoglobulin M antibody response during acute infection. J Clin Microbiol 33: 1927 – 1930, 1995.PubMedGoogle Scholar
  43. 43.
    . Maine, GT, Lazzarotto, T, Chovan, LE, Flanders, R, and Landini, MP. The DNA-binding protein pUL57 of human Cytomegalovirus: Comparison of specific Immunoglobulin M (IgM) reactivity with IgM reactivity to other major terget antigens. Clin Diag Lab Immunol 3: 358 – 360, 1996.Google Scholar
  44. 44.
    . Landini MP, Lazzarotto T, Maine GT, Ripalti A, Flanders R. recombinant mono and poly antigens to detect Cytomegalovirus-specific IgM in human sera by enzyme immunoassay. J Clin Microbiol 1995; submitted.Google Scholar
  45. 45.
    . Weber W, Nestler U, Ernst W, Rabenau H, Braner J, Birkenbach A, Scheuermann EH, Schoeppe W, Doerr HW. Low correlation of human cytomegalovirus DNA amplification byn polymerase chain reaction with cytomegalovirus disease in organ transplant recipients. J Med Virol. 1994; 43: 187 – 193.PubMedCrossRefGoogle Scholar
  46. 46.
    . Ghisetti V, Barbui A, Lazzarotto T, Donegani E, Ripalti A, Dal Monte P Bobbio, di Summa M, Marchiaro G, Landini MP. Comparison between virology and serology for the follow upof cytomegalovirus infection in heart transplant recipients. Transplantation, submitted.Google Scholar
  47. 47.
    . Landini MP, Lazzarotto T, Ripalti A, Guan MX, La Placa M. Antibody response to recombinant Lambda gt11 fusion proteins in Cytomegalovirus infection. J Clin Microbiol 1989; 27: 2324 – 2327.PubMedGoogle Scholar
  48. 48.
    . Basson J, Tardy JC, Aymard M. Characterization of immune complexes containing Cytomegalovirus-specific IgM antibodies following a kidney graft. J Med Virol 1991; 33: 205 – 210.PubMedCrossRefGoogle Scholar
  49. 49.
    . Strand OA, Hoddevik GM The diagnostic significance of specific serum IgA detection in Cytomegalovirus infection. Archives of Virology 1984; 82: 173 – 180.PubMedCrossRefGoogle Scholar
  50. 50.
    . Morris GE, Coleman RM, Best JM, Benetato BB, Nahmias AJ Persistence of serum IgA antibodies to herpes simplex, Varicella Zoster, Cytomegalovirus and Rubella virus detected by enzyme-linked immunosorbent assays. Journal of Medical Virology 1985; 16: 343 – 349.PubMedCrossRefGoogle Scholar
  51. 51.
    . Vargas, MA, Bertrand, F, Mulongo, N, Squifflet, JP, Lamy, ME. Specific IgE detected by ELISA and immunoblott after human cytomegalovirus infection in renal transplant recipients. Clin Diag Virol 6: 1 – 9, 1996.CrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1996

Authors and Affiliations

  • Maria Paola Landini
    • 1
    • 2
  • Tiziana Lazzarotto
    • 1
  • Paola Dal Monte
    • 1
  1. 1.Section of Microbiology Department of Clinical and Experimental MedicineUniversity of BolognaItaly
  2. 2.Institute of MicrobiologyUniversity of Bologna, St. Orsola General HospitalBolognaItaly

Personalised recommendations